Fortrea Holdings Inc

Fortrea Holdings Inc(FTRE)股票分析

$22.490

-0.252 (-1.12%)收盤時

Loading chart…
最高
23.135
開盤
23.040
成交量加權均價
22.50
成交量
1.90M
市值
2.04B
最低
21.860
成交金額
42.79M
企業價值/稅息折舊攤銷前利潤(TTM)
20.85

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide.

AI 分析 of Fortrea Holdings Inc (FTRE)

買進

Fortrea Holdings Inc is a good buy right now, trading at $22.49 with a forward P/E of 12.14, indicating potential for growth relative to earnings. The stock has shown a strong 1-year change of +115.83%, reflecting significant appreciation over the past year. However, the main risk is the insider selling, which has increased by 267.54% over the last month, suggesting potential concerns about the company's future performance.

估值指標

Fortrea Holdings Inc(FTRE)目前預期本益比為 12.14,5 年平均預期本益比為 22.69。

預期本益比

合理
5 年均值 P/E
22.69
目前P/E
12.14
高估
38.24
低估
7.13

預期 EV/EBITDA

高估
5 年均值 EV/EBITDA
12.58
目前EV/EBITDA
20.85
高估
18.69
低估
6.47

預期股價營收比

合理
5 年均值 P/S
0.64
目前P/S
0.79
高估
0.92
低估
0.35

Alphio AI 對 FTRE 的價格情境

情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

樂

樂觀

樂觀 · 25%FTRE

$4.04

情境價格

基

基準

基準 · 50%FTRE

$3.61

情境價格

悲

悲觀

悲觀 · 25%FTRE

$2.97

情境價格

持有 FTRE 的大戶

A

Ausbil Investment Management Limited

+ 持有FTRE

-3.43%

3個月報酬率

S

Sessa Capital IM, L.P.

+ 持有FTRE

-13.55%

3個月報酬率

事件時間軸

2026-09-02 (ET)

07:30:00

Fortrea Acquires Worldwide's Early Phase Services Division for $45M

2026-07-29 (ET)

07:00:00

Raises FY26 Adjusted EBITDA Outlook to $205M-$220M

2026-06-26 (ET)

09:30:00

Nasdaq Futures Decline as Tech Stocks Weaken

07:30:00

Fortrea Appoints Jason Knoblauch as CFO

資訊

FTRE 常見問題 —— 由 Alphio AI 解答

Fortrea Holdings Inc. is a global contract research organization (CRO), which provides clinical development solutions to the life sciences industry. The Company is engaged in providing biopharmaceutical product and medical device development services to pharmaceutical, biotechnology and medical device customers. The Company offers customers flexible delivery models that include full service, functional service provider, and hybrid service structures. It provides phase I-IV clinical trial management, clinical pharmacology and consulting services. The Company manages its business through a single segment, Clinical Services, that provides services across the clinical pharmacology and clinical development spectrum. The Company has access to all key markets worldwide through a footprint of primary office locations in five countries (the United States, the United Kingdom, China, India and Singapore) with field operations in other jurisdictions worldwide. It operates in the Healthcare sector (SERVICES-MEDICAL LABORATORIES industry).

Fortrea Holdings Inc is a good buy right now, trading at $22.49 with a forward P/E of 12.14, indicating potential for growth relative to earnings. The stock has shown a strong 1-year change of +115.83%, reflecting significant appreciation over the past year. However, the main risk is the insider selling, which has increased by 267.54% over the last month, suggesting potential concerns about the company's future performance.

暫無貼文

註冊或登入後參與討論

本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。

開始交易